Phentolamine
Oraverse, Ryzumvi (phentolamine) is a small molecule pharmaceutical. Phentolamine was first approved as Regitine on 1982-01-01. It is used to treat extravasation of diagnostic and therapeutic materials, malignant hypertension, and necrosis in the USA. The pharmaceutical is active against alpha-1A adrenergic receptor, alpha-1B adrenergic receptor, and alpha-1D adrenergic receptor. In addition, it is known to target alpha-2B adrenergic receptor, alpha-2A adrenergic receptor, and alpha-2C adrenergic receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Trade Name
FDA
EMA
Oraverse, Ryzumvi (generic drugs available since 1998-03-11, discontinued: Regitine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| oraverse | New Drug Application | 2018-12-05 |
| phentolamine mesylate | ANDA | 2024-08-19 |
| ryzumvi | New Drug Application | 2023-11-15 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| necrosis | — | D009336 | — |
| extravasation of diagnostic and therapeutic materials | — | D005119 | — |
| malignant hypertension | EFO_1001031 | D006974 | — |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
PHENTOLAMINE MESYLATE, RYZUMVI, FAMYGEN LIFE SCI | |||
| 2026-09-25 | NP | ||
ATC Codes
C: Cardiovascular system drugs
— C04: Peripheral vasodilators
— C04A: Peripheral vasodilators
— C04AB: Imidazoline derivatives, peripheral vasodilators
— C04AB01: Phentolamine
V: Various drug classes in atc
— V03: All other therapeutic products
— V03A: All other therapeutic products
— V03AB: Antidotes
— V03AB36: Phentolamine
HCPCS
Code | Description |
|---|---|
| J2760 | Injection, phentolamine mesylate, up to 5 mg |
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vasodilation | D014664 | — | — | 2 | — | — | 1 | 1 | 4 |
| Dental anesthesia | D000766 | — | — | — | 1 | 2 | 1 | — | 4 |
| Local anesthesia | D000772 | — | — | — | — | — | 2 | 1 | 3 |
| Vasoconstriction | D014661 | — | — | 1 | — | — | 1 | 1 | 3 |
| Pre-eclampsia | D011225 | EFO_0000668 | O14 | — | — | — | 1 | 1 | 2 |
| Eclampsia | D004461 | HP_0100601 | O15 | — | — | — | 1 | 1 | 2 |
| Multiple myeloma | D009101 | — | C90.0 | — | — | — | 1 | — | 1 |
| Plasma cell neoplasms | D054219 | — | — | — | — | — | 1 | — | 1 |
| Neoplasm metastasis | D009362 | EFO_0009708 | — | — | — | — | 1 | — | 1 |
| Pregnancy complications | D011248 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | 1 | 1 | — | 1 | 4 |
| Pathologic dilatation | D004108 | — | — | — | 1 | 3 | — | — | 4 |
| Dilatation | D004106 | — | — | — | 1 | 3 | — | — | 4 |
| Mydriasis | D015878 | HP_0011499 | H57.04 | — | 1 | 3 | — | — | 4 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 1 | — | 2 | 3 |
| Presbyopia | D011305 | — | H52.4 | — | 1 | 2 | — | — | 3 |
| Covid-19 | D000086382 | — | — | — | 1 | 2 | — | — | 2 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | 1 | 1 | 1 | — | — | 2 |
| Ischemic stroke | D000083242 | — | — | — | — | 1 | — | — | 1 |
| Ischemia | D007511 | EFO_0000556 | — | — | — | 1 | — | — | 1 |
Show 14 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Erectile dysfunction | D007172 | EFO_0004234 | F52.21 | 1 | 1 | — | — | 1 | 3 |
| Prostatic neoplasms | D011471 | — | C61 | — | 1 | — | — | 1 | 2 |
| Ocular hypertension | D009798 | EFO_1001069 | H40.0 | — | 1 | — | — | — | 1 |
| Glaucoma | D005901 | EFO_0000516 | H40 | — | 1 | — | — | — | 1 |
| Open-angle glaucoma | D005902 | EFO_0004190 | H40.1 | — | 1 | — | — | — | 1 |
| Hypesthesia | D006987 | HP_0003474 | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | — | — | — | — | 3 |
| Healthy volunteers/patients | — | — | — | 3 | — | — | — | — | 3 |
| Heart failure | D006333 | HP_0001635 | I50 | 1 | — | — | — | 1 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | — | — | — | 1 | 2 |
| Hypoglycemia | D007003 | HP_0001943 | E16.2 | 1 | — | — | — | 1 | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Pulmonary arterial hypertension | D000081029 | — | — | 1 | — | — | — | — | 1 |
| Obstructive lung diseases | D008173 | HP_0006536 | — | 1 | — | — | — | — | 1 |
| Vasculogenic impotence | D018783 | EFO_1001234 | — | 1 | — | — | — | — | 1 |
| Stem cell transplantation | D033581 | — | — | 1 | — | — | — | — | 1 |
Show 4 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Cerebral hemorrhage | D002543 | — | — | — | — | — | — | 2 | 2 |
| Pneumonia | D011014 | EFO_0003106 | — | — | — | — | — | 1 | 1 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | — | — | — | — | 1 | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Hypotension | D007022 | EFO_0005251 | I95 | — | — | — | — | 1 | 1 |
| Preoperative period | D057234 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Phentolamine |
| INN | phentolamine |
| Description | Phentolamine is a substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension. It has a role as an alpha-adrenergic antagonist and a vasodilator agent. It is a member of imidazoles, a member of phenols, a tertiary amino compound and a substituted aniline. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cc1ccc(N(CC2=NCCN2)c2cccc(O)c2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 50-60-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL597 |
| ChEBI ID | 8081 |
| PubChem CID | 5775 |
| DrugBank | DB00692 |
| UNII ID | Z468598HBV (ChemIDplus, GSRS) |
Target
Agency Approved
ADRA1A
ADRA1A
ADRA1B
ADRA1B
ADRA1D
ADRA1D
Organism
Homo sapiens
Gene name
ADRA1A
Gene synonyms
ADRA1C
NCBI Gene ID
Protein name
alpha-1A adrenergic receptor
Protein synonyms
Alpha-1A adrenoceptor, Alpha-1A adrenoreceptor, Alpha-1C adrenergic receptor, Alpha-adrenergic receptor 1c, G protein coupled receptor
Uniprot ID
Mouse ortholog
Adra1a (11549)
alpha-1A adrenergic receptor (Q8BV77)
Alternate
ADRA2B
ADRA2B
ADRA2A
ADRA2A
ADRA2C
ADRA2C
Organism
Homo sapiens
Gene name
ADRA2B
Gene synonyms
ADRA2L1, ADRA2RL1
NCBI Gene ID
Protein name
alpha-2B adrenergic receptor
Protein synonyms
ADRA2B adrenergic, alpha-2B-, receptor, Alpha-2 adrenergic receptor subtype C2, alpha-2-adrenergic receptor-like 1, Alpha-2B adrenoceptor, Alpha-2B adrenoreceptor, Alpha-2BAR, G-protein coupled receptor
Uniprot ID
Mouse ortholog
Adra2b (11552)
alpha-2B adrenergic receptor (P30545)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,921 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
165 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use